Alys Pharmaceuticals chair Francesco De Rubertis (L) and COO Thibaud Portal

Centes­sa 2.0 with a twist: Medicxi com­bines six im­muno-derm star­tups with $100M

Eu­ro­pean biotech in­vestor Medicxi is bring­ing six star­tups un­der one roof to form an im­muno-der­ma­tol­ogy drug­mak­er with 14 pipeline projects in a move rem­i­nis­cent of its 10-in-1 Centes­sa Phar­ma­ceu­ti­cals un­veil­ing in 2021.

The health­care in­vest­ment firm will pump $100 mil­lion in fi­nanc­ing in­to the Boston and Gene­va-based biotech named Alys Phar­ma­ceu­ti­cals. It’s an amal­ga­ma­tion of Alde­na Ther­a­peu­tics, Graegis Phar­ma­ceu­ti­cals, Gran­u­lar Ther­a­peu­tics, Klir­na Biotech, Ni­ra Bio­sciences and Vimela Ther­a­peu­tics. Those make up the ma­jor­i­ty of the sev­en im­muno-derm star­tups Medicxi in­vest­ed in over the past few years, but the first, vi­tili­go drug­mak­er Vil­laris Ther­a­peu­tics, al­ready sold to In­cyte.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.